超极化MRI分子探针在动物模型中可视化PON酶活性
MRI advance could help monitor fatty liver disease by revealing enzyme activity
日本研究团队开发出基于碳-13标记MVL的超极化MRI分子探针,可在体内高灵敏地显示肝细胞色素P450旁路酶(PON)活性。在MASLD和MASH小鼠模型中,随着疾病进展PON活性逐步下降;信号增强约23万倍,扫描约20秒即可完成肝脏成像。相关研究发表于Sensors & Diagnostics。
Researchers in Japan have, for the first time, visualized the activity of an important liver enzyme in vivo using an MRI-based approach, potentially providing a new way to detect and monitor fatty liver disease. The condition can progress with few obvious warning signs and, in severe cases, can lead to liver inflammation, fibrosis, cirrhosis and liver cancer.
A joint research team led by Yoichi Takakusagi at the National Institutes for Quantum Science and Technology (QST), together with Daichi Kaneko and Akari Ikeda of Nippon Sanso Corp. and other collaborators, developed a molecular probe that enables the activity of an enzyme called paraoxonase (PON) to be visualized using hyperpolarized MRI.
In mouse models of metabolic dysfunction–associated steatotic liver disease (MASLD) and its more severe inflammatory form, metabolic dysfunction–associated steatohepatitis (MASH), the researchers found that PON activity declined as the disease progressed.
This study is published in Sensors & Diagnostics.
A liver marker beyond blood tests
MASLD is a common condition in which excess fat builds up in the liver in association with metabolic disorders. It is estimated to affect about one in three adults. In some people, the disease progresses to MASH, liver fibrosis, cirrhosis and even liver cancer.
PON, which is mainly produced in the liver, is involved in lipid metabolism and protecting against oxidative stress. Its activity has therefore attracted attention as a potential marker of metabolic changes in the liver. However, conventional blood tests cannot accurately reflect how the enzyme functions within the liver itself, where its activity is strongly influenced by the local biological environment.
Amplifying the enzyme signal
To make that activity visible, the team designed a probe based on carbon-13-labeled mevalonolactone, or [1-¹³C]MVL. PON converts MVL into mevalonic acid (MVA). By detecting both molecules and comparing their signals, the researchers can visualize PON activity in the liver.
The researchers used a technique called hyperpolarization to temporarily boost the probe's MRI signal. Using a SpinAligner hyperpolarizer installed at QST's Institute for Quantum Life Science, the team achieved approximately 230,000-fold signal enhancement compared with conventional MRI conditions. The enhanced signal persisted long enough to detect both the probe and its metabolic product in vivo. In mice, a scan of about 20 seconds was sufficient to visualize PON activity in the liver.
Tracking disease progression in mice
The team then tested the approach in mice fed a special diet that induces MASLD and MASH. Compared with healthy control mice, the disease-model mice showed a progressive decline in liver PON activity as the disease progressed. These findings show that the probe can noninvasively detect disease-associated changes in enzyme activity in the living liver with high sensitivity.
"We wanted to find a way to see what enzymes are actually doing inside the living body, rather than relying only on blood tests," said Takakusagi, group leader at QST's Institute for Quantum Life Science. "The biggest challenge was developing a probe that produced a strong enough signal while still responding specifically to PON activity. Our new probe overcame that hurdle, allowing us to visualize changes in enzyme activity associated with the progression of fatty liver disease."
The researchers say the implications could eventually extend beyond liver disease. By adapting the molecular probe design to other enzymes, hyperpolarized MRI could open the way to a new class of imaging methods that visualize biochemical activity rather than anatomical changes alone. In the longer term, such techniques could contribute to earlier disease detection, assessment of disease progression and more individualized treatment planning.
More information
Daichi Kaneko et al., A hyperpolarized 13 C MRI molecular probe for in vivo imaging of paraoxonase activity, Sensors & Diagnostics (2026). DOI: 10.1039/d6sd00164e
Who's behind this story?
Swati Mestri
Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: MRI advance could help monitor fatty liver disease by revealing enzyme activity (2026, November 18) retrieved 18 November 2026 from https://medicalxpress.com/news/2026-11-mri-advance-fatty-liver-disease.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com